UNLIMITED · UNderstanding Lipid ImmunoMetabolIsm To trEat Disease

Линиите свързват координатора с партньорите.

Накратко на български

Цел на проекта

The UNLIMITED project addresses the critical challenges of lipid immunometabolism, a rapidly emerging field with transformative potential for treating immune-mediated diseases such as cancer, autoimmunity and metabolic disorders. Lipid metabolism has been recently recognized as a regulator of immune cell function, yet the intricate interactions between lipid pathways and immune responses within tissue-specific microenvironments remain poorly understood. This knowledge gap hampers the development of precision therapies tailored to the metabolic needs of immune cells in diverse tissue niches. To tackle these challenges, UNLIMITED will train 15 Doctoral Candidates in cutting-edge interdisciplinary research, equipping them with expertise spanning immunology, bioinformatics, metabolism, and drug development. A key feature of UNLIMITED training programme is the integration of leading-edge methodologies, such as multi-omics machine learning, single-cell technologies, CRISPR-Cas9, and spatial metabolomics, alongside groundbreaking techniques pioneered by consortium partners, including SCENITH, Met-Flow, click-chemistry, LIPSTIC, and advanced lipidomics. UNLIMITED’s training program emphasizes a holistic, interdisciplinary approach, providing DCs with technical skills, unparalleled expertise, and transferable competencies to thrive in academic and industrial sectors. The project will unlock unprecedented insights into how lipid metabolic pathways regulate immune cell function and adapt to changes in the tissue microenvironment. This knowledge will enable the identification of novel therapeutic targets and pioneering precision therapies for immune-related diseases. This bold initiative strengthens Europe’s leadership in health innovation, creating a new generation of highly skilled researchers ready to transform global healthcare and advance therapeutic frontiers.

Оригинален текст от CORDIS (на английски).

Участници

• UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ · MainzКоординаторГермания
• ACADEMISCH ZIEKENHUIS LEIDEN · LeidenНидерландия
• ActiTrexx GmbH · MainzГермания
• BIOCRATES LIFE SCIENCES AG · INNSBRUCKАвстрия
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisФранция
• CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) · MadridИспания
• JOHANNES GUTENBERG-UNIVERSITAT MAINZ · MainzГермания
• LUXEMBOURG INSTITUTE OF HEALTH · StrassenЛюксембург
• MEDIZINISCHE UNIVERSITAET WIEN · WienАвстрия
• SAMPLIX ApS · BIRKERODДания
• SANOFI-AVENTIS DEUTSCHLAND GMBH · Frankfurt Am MainГермания
• STICHTING AMSTERDAM UMC · AmsterdamНидерландия
• STICHTING VU · AmsterdamНидерландия
• Sitryx Therapeutics Ltd · OxfordОбединеното кралство
• Sonja NossГермания
• TECHNISCHE UNIVERSITAET BRAUNSCHWEIG · BraunschweigГермания
• THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinИрландия
• THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN · AberdeenОбединеното кралство
• Tress Academic GbR · PlaneggГермания
• UNIVERSIDAD AUTONOMA DE MADRID · MadridИспания
• UNIVERSITA DEGLI STUDI DI MILANO · MilanoИталия
• UNIVERSITA DEGLI STUDI DI PADOVA · PadovaИталия
• UNIVERSITAT ZU KOLN · KolnГермания
• UNIVERSITE D'AIX MARSEILLE · MarseilleФранция
• UNIVERSITE DU LUXEMBOURG · ESCH-SUR-ALZETTEЛюксембург
• VILNIAUS UNIVERSITETAS · VilniusЛитва
• VUGENE UAB · KaunasЛитва

Връзки

• Виж в CORDIS
• DOI: 10.3030/101227259